Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Inhibition of FAK kinase activity preferentially targets cancer stem cells.

Kolev VN, Tam WF, Wright QG, McDermott SP, Vidal CM, Shapiro IM, Xu Q, Wicha MS, Pachter JA, Weaver DT.

Oncotarget. 2017 Jun 16;8(31):51733-51747. doi: 10.18632/oncotarget.18517. eCollection 2017 Aug 1.

2.

Pyk2 promotes tumor progression in multiple myeloma.

Zhang Y, Moschetta M, Huynh D, Tai YT, Zhang Y, Zhang W, Mishima Y, Ring JE, Tam WF, Xu Q, Maiso P, Reagan M, Sahin I, Sacco A, Manier S, Aljawai Y, Glavey S, Munshi NC, Anderson KC, Pachter J, Roccaro AM, Ghobrial IM.

Blood. 2014 Oct 23;124(17):2675-86. doi: 10.1182/blood-2014-03-563981. Epub 2014 Sep 12.

3.

STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2.

Tam WF, Hähnel PS, Schüler A, Lee BH, Okabe R, Zhu N, Pante SV, Raffel G, Mercher T, Wernig G, Bockamp E, Sasca D, Kreft A, Robinson GW, Hennighausen L, Gilliland DG, Kindler T.

Cancer Res. 2013 Jan 1;73(1):373-84. doi: 10.1158/0008-5472.CAN-12-0255. Epub 2012 Nov 13.

4.

Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening.

Rickles RJ, Tam WF, Giordano TP 3rd, Pierce LT, Farwell M, McMillin DW, Necheva A, Crowe D, Chen M, Avery W, Kansra V, Nawrocki ST, Carew JS, Giles FJ, Mitsiades CS, Borisy AA, Anderson KC, Lee MS.

Mol Cancer Ther. 2012 Jul;11(7):1432-42. doi: 10.1158/1535-7163.MCT-11-0925. Epub 2012 Apr 3.

5.

Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies.

Rickles RJ, Pierce LT, Giordano TP 3rd, Tam WF, McMillin DW, Delmore J, Laubach JP, Borisy AA, Richardson PG, Lee MS.

Blood. 2010 Jul 29;116(4):593-602. doi: 10.1182/blood-2009-11-252668. Epub 2010 Apr 9.

6.

Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells.

Tam WF, Gu TL, Chen J, Lee BH, Bullinger L, Fröhling S, Wang A, Monti S, Golub TR, Gilliland DG.

Blood. 2008 Sep 1;112(5):1981-92. doi: 10.1182/blood-2007-07-103010. Epub 2008 Jun 17.

7.

Can FLT3 inhibitors overcome resistance in AML?

Tam WF, Gary Gilliland D.

Best Pract Res Clin Haematol. 2008 Mar;21(1):13-20. doi: 10.1016/j.beha.2007.11.003. Review.

PMID:
18342808
8.
9.

IkappaB family members function by different mechanisms.

Tam WF, Sen R.

J Biol Chem. 2001 Mar 16;276(11):7701-4. Epub 2001 Jan 10.

10.
11.

c-Rel is a target of pentoxifylline-mediated inhibition of T lymphocyte activation.

Wang W, Tam WF, Hughes CC, Rath S, Sen R.

Immunity. 1997 Feb;6(2):165-74.

Supplemental Content

Support Center